Tirzepatide in kidney transplant candidates: a pilot study
Phase 2
- Conditions
- ObesityEnd-stage renal diseaseRenal and Urogenital - Kidney diseaseMetabolic and Endocrine - Metabolic disorders
- Registration Number
- ACTRN12624000665538
- Lead Sponsor
- St Vincent's Hospital Melbourne
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- All
- Target Recruitment
- 8
Inclusion Criteria
18 years or older at the time of enrolment
Obesity (body mass index [BMI] of 30 kg/m2 or above)
ESKD, requiring haemodialysis, at the time of enrolment
Considered a potential candidate for kidney transplantation
Can provide informed consent
Exclusion Criteria
Previous or planned (during the trial period) bariatric surgery
Type 1 diabetes
History of acute or chronic pancreatitis
Personal or first-degree relative history of multiple endocrine neoplasia type 2 or medullary Thyroid carcinoma
Proliferative diabetic retinopathy requiring acute treatment
Pregnancy, lactation, or plan to become pregnant within 28 weeks of enrolment
Known hypersensitivity to tirzepatide
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method